Switzerland· 57918001
Octaplex 500, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
A coagulation factor ix, ii, vii and x in combination product, registered in Switzerland by Octapharma AG and dispensed under Swissmedic category B. The same ATC class is registered in 11 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix, ii, vii and x in combination is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD01 (coagulation factor ix, ii, vii and x in combination), each read from that country’s own register.
- This record: Switzerland
- 7 of them publish a price we can compare per daily dose
Coagulation factor ix, ii, vii and x in combination · ATC B02BD01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
- Manufacturer
- Octapharma AG
- Country
- Switzerland (CH)
- ATC code
- B02BD01
- ATC class
- Coagulation factor IX, II, VII and X in combination
- Defined daily dose
- 1.6 TSD, E
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix, ii, vii and x in combination.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix, ii, vii and x in combination · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B02BD01
Coagulation factor ix, ii, vii and x in combination, as other registers publish it.
- CzechiaBERIPLEXCSL Behring GmbH, Marburg
- CzechiaBERIPLEXCSL Behring GmbH, Marburg
- SwitzerlandBeriplex P/N 1000
- PolandBeriplex P/N 1000CSL Behring GmbH
- CanadaBERIPLEX P/N 1000CSL BEHRING CANADA INC
- NetherlandsBeriplex P/N 1000 IE, poeder en oplosmiddel voor oplossing voor injectieCSL Behring GmbH
- IrelandBeriplex P/N 1000 IU, powder and solvent for solution for injectionCSL Behring GmbH
- SwitzerlandBeriplex P/N 1000, Pulver und Lösungsmittel zur Herstellung einer InjektionslösungCSL Behring AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2943621-a245-4160-9f8f-dfb907e2c47e GET /v1/drugs/f2943621-a245-4160-9f8f-dfb907e2c47e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Blutprodukte"
}See everything about coagulation factor ix, ii, vii and x in combination.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.